ReviewJournal of the American Academy of Dermatology2020
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.
Review in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Novel Strategy in the Detection of Adverse Cutaneous Drug Reactions: A Case Series Study.Diagnostics (Basel, Switzerland) · 2024Article
- Dermatological Manifestations in COVID-19: A Case Study of SARS-CoV-2 Infection in a Genetic Thrombophilic Patient with Mthfr Mutation.Pathogens (Basel, Switzerland) · 2023Article
- Recent developments in the immunopathology of COVID-19.Allergy · 2023Review
- Successful Desensitization to Remdesivir Hypersensitivity in a Patient Undergoing Treatment for COVID-19.The Annals of pharmacotherapy · 2023Article
- Effects of Vitamin C on the Oral-Nasal Mucosal Damage Caused by Favipiravir in Old and Young Rats.Cureus · 2022Article
- Cutaneous manifestations of COVID-19: diagnosis and management.The Medical journal of Australia · 2022Article
- The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis.Chinese medicine · 2022Review
- Mucocutaneous lesions associated with SARS-CoV-2 infection (Review).Experimental and therapeutic medicine · 2022Review
- Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection.Clinical case reports · 2022Article
- Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19.Clinical and experimental dermatology · 2022Article
- Fluorescence in the Sclera, Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections.The Journal of clinical and aesthetic dermatology · 2022Article
- Molecular docking and molecular dynamics study Lianhua Qingwen granules (LHQW) treats COVID-19 by inhibiting inflammatory response and regulating cell survival.Frontiers in cellular and infection microbiology · 2022Article
- Current Perspectives on Severe Drug Eruption.Clinical reviews in allergy & immunology · 2021Review
- Review
- Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test.Contact dermatitis · 2021Article
- Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment.Journal of cosmetic dermatology · 2021Article
- Article
- Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans.Dermatologic therapy · 2021Article
- Defining the short-term and long-term skin manifestations of COVID-19: insights after more than three years of the pandemic.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
- Clinicopathologic correlations of COVID-19-related cutaneous manifestations with special emphasis on histopathologic patterns.Clinics in dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new coronavirus, severe acute respiratory syndrome coronavirus 2, is associated with a wide variety of cutaneous manifestations. Although new skin manifestations caused by COVID-19 are continuously being described, other cutaneous entities should also be considered in the differential diagnosis, including adverse cutaneous reactions to drugs used in the treatment of COVID-19 infections. The aim of this review is to provide dermatologists with an overview of the cutaneous adverse effects associated with the most frequently prescribed drugs in patients with COVID-19. The skin reactions of antimalarials (chloroquine and hydroxychloroquine), antivirals (lopinavir/ritonavir, ribavirin with or without interferon, oseltamivir, remdesivir, favipiravir, and darunavir), and treatments for complications (imatinib, tocilizumab, anakinra, immunoglobulins, corticosteroids, colchicine and low molecular weight heparins) are analyzed. Information regarding possible skin reactions, their frequency, management, and key points for differential diagnosis are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.